Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Galectin-3 Expression Seborrheic Keratosis

Am J Dermapathol; ePub 2017 Oct 1; Jiang, et al

Galectin-3 has been suggested relative to tumor genesis, progression, and metastasis in basal cell carcinoma and squamous cell carcinoma that are the most common skin cancers characterized by malignant epidermal proliferation. In this study, researchers evaluated galectin-3 expression in seborrheic keratosis, keratoacanthoma, and infectious diseases including verruca vulgaris, condyloma acuminatum, and chromoblastomycosis that are pathologically featured by benign epidermal proliferation. Galectin-3 expression was shown by immunohistochemical staining and quantified using the Image Pro Plus V6.0. They found:

  • Galectin-3 distributed evenly in normal skin around the body decreased significantly in all selected diseases compared with healthy controls, but it was comparable among each disease.
  • These findings imply that galectin-3 does not differentiate between benign and malignant proliferation of keratinocytes.

Citation:

Jiang Z, Tan G, Shi Z, Zhang Y, Han Y, Wang L. Galectin-3 expression in benign and malignant skin diseases with epidermal hyperplasia. [Published online ahead of print October 1, 2017]. Am J Dermapathol. doi:10.1097/DAD.0000000000000781.